The first treatment ever of cancer by radioimmunotherapy (RIT) was performed by William H. Beierwaltes in 1951 and was a success [1] . However, experimentation on this approach really started in 1981 with polyclonal antibodies [2] and radiolabelled monoclonal antibodies were proposed for this purpose by several groups in 1987 and 1988. Research on radioimmunotherapy became more and more active over the years and finally, in 2002 and 2003, radiolabelled monoclonal antibodies, both targeting the CD20 antigen, were approved for marketing for the treatment of follicular non-Hodgkin's lymphoma.
On the other side, immunotoxins were described in 1981 with a pretty advanced description of monoclonal antibodyricin A conjugates [3] . Research in this field was extremely active and many antibodies as well as many different vegetal and bacterial toxins were tested. Toxicity always limited the clinical efficacy with vascular leak syndrome preventing further development in most cases [4] . Shifting from protein toxins to smaller molecules, derived from calicheamicin, auristatin or maytansin, provided better in vivo results [4] and gemtuzumab ozogamicin, an anti-CD33 humanized antibody coupled to calicheamicin obtained market approval in 2000 for the treatment of acute myeloid leukaemia [5] .
Since then, many new radiolabelled antibodies have been proposed, against a variety of antigens, and some have reached the clinic, with good results in haematological diseases and more contrasted outcomes in solid tumours, although evidence of clinical efficacy has been obtained in the treatment of residual disease in metastatic colon cancer [6] or in medullary thyroid carcinoma using a pretargeting technique [7] . The use of alpha particle-emitting radionuclides [8] , potentially toxic but also efficient against isolated cells thanks to their high lineic energy transfer, has been proposed for several indications, both in haematological diseases and solid tumours, intracavitary administration being often proposed for the treatment of residual disease. It is expected that alpha particle-emitting radionuclides overwhelm tumour resistance mechanisms by producing clusters of DNA double-stranded breaks (DSB). 211 At, a cyclotron-produced alpha-emitting radionuclide with relatively long half-life (7.2 h), is one of a few candidates for targeted alpha-radionuclide therapy [9] . Dose-limiting toxicity is generally haematological, although potential long-term toxicity of alpha-emitting radionuclides is not well known yet.
For the immunotoxin approach, many antibodies conjugated to highly toxic drugs derived from microorganismproduced toxins are in clinical development [10, 11] . Dose-limiting toxicity appears to be a vaso-occlusive syndrome. Even if the toxins are able to kill chemoresistant tumour cells, gemtuzumab ozogamicin (anti-CD33 conjugated to calicheamicin) is not sufficient to induce persistent complete remission because of resistance mechanisms of leukaemic cells. Since 2008 the clinical use of gemtuzumab ozogamicin is no longer recommended in Europe by the European Medicines Agency (EMEA) because of the combination of poor efficacy and considerable side effects.
Thus for both immunotoxins and antibody-targeted alpha-emitting radionuclides, a very potent agent, the toxin or the alpha-emitting radionuclide, with little if any capacity to be less toxic to normal tissues than to tumour cells, is proposed to treat cancer diseases. In their paper, entitled "In vitro experimental 211 At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin", Petrich et al. have confronted both approaches in a series of in vitro experiments using an anti-CD33 monoclonal antibody labelled with 211 At or gemtuzumab ozogamicin. Survival of leukaemic HL-60 and K-562 cells treated with the 211 Atlabelled antibody, gemtuzumab ozogamicin or control unlabelled antibody were compared. Treatment-induced caspase 3/7 activity, DNA fragmentation and necrosis in HL-60 cells were also compared. As expected, antigen density-dependent specific binding of the antibodies to leukaemic cells was observed and could be specifically blocked by unlabelled anti-CD33. Used at the same antibody concentration, both the 211 At-labelled anti-CD33 antibody and gemtuzumab ozogamicin were equally potent in induction of apoptosis or necrosis or DNA DSB or in decreasing cell survival.
Interestingly, only 1 in 1,090 antibody molecules actually carried an astatine atom, versus all antibodies carrying at least one toxin molecule in gemtuzumab ozogamicin, with a mean of 2-3 toxins per antibody. If gemtuzumab ozogamicin was used at the same toxin agent concentration (astatine versus toxin), then it was no longer effective against the leukaemic cells.
This observation tells us that antibodies labelled at higher specific activities could be more potent than immunotoxins. This assumes that injected astatine activities may be escalated, but today there is very little information available on the toxicity of astatine-labelled antibodies injected systemically. Most preclinical and clinical studies have been conducted using locoregional administration under conditions where the injected activity was mostly confined to the site of injection.
Nevertheless, results presented in the paper suggest that 211 At-labelled antibodies, being as potent as and potentially more potent than immunotoxins, are promising, highly cytotoxic radiopharmaceuticals for cancer radioimmunotherapy, which is very good news for nuclear medicine. The authors also state that labelling techniques must be further improved to afford higher yields and specific activities because low specific activity (only 1 labelled antibody molecule in 1,000) limits anti-tumour efficacy when tumour-specific epitopes are sparse. This, and increased availability of 211 At, are some of the challenges that we are facing today.
